Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 10 of 151

  1. ALECTINIB

    Hoffmann-La Roche

    ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available

    phase 2 small molecule active

    1 trial

  2. ALG-000184

    Aligos Therapeutics

    Chronic Hepatitis B Infection

    phase 2 small molecule active

    1 trial

  3. ALG-000184-202

    Aligos Therapeutics

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial

  4. ALG-055009

    Aligos Therapeutics

    NASH

    phase 2 small molecule completed

    1 trial

  5. ALG.APV-527

    Aptevo Therapeutics

    Solid Tumor

    phase 2 small molecule active

    1 trial

  6. ALKS 2680-201

    Alkermes Pharma Ireland

    Narcolepsy Type 1

    phase 2 small molecule active

    1 trial

  7. ALKS 2680-202

    Alkermes Pharma Ireland

    Narcolepsy Type 2

    phase 2 small molecule active

    1 trial

  8. ALKS 2680-203

    Alkermes Pharma Ireland

    Idiopathic Hypersomnia (IH)

    phase 2 small molecule active

    1 trial

  9. ALKS4230-006

    Wuhan Createrna Science and Technology Co., Ltd

    Advanced cutaneous melanoma and Advanced mucosal melanoma

    phase 2 small molecule active

    1 trial

  10. ALL2418

    Fondazione Telethon ETS

    Acute B-cell Lymphoblastic Leukemia with minimal residual positive disease prior to haematopoietic stem cell transplantation in adult patients

    phase 2 small molecule active

    1 trial

  11. ALL2620

    Fondazione Telethon ETS

    Ph+ Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  12. ALL3024

    Fondazione Telethon ETS

    Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  13. ALLO-501A

    Allogene Therapeutics

    Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

    phase 2 gene therapy active

    1 trial

  14. ALLO-605

    Allogene Therapeutics

    Relapsed/Refractory Multiple Myeloma

    phase 2 gene therapy terminated

    1 trial

  15. ALLO-647

    Allogene Therapeutics

    Relapsed/Refractory Large B Cell Lymphoma

    phase 2 mab terminated

    1 trial

  16. ALLO-HPV

    Astra Zeneca AB

    Recipients of allogeneic stem cell transplantation

    phase 2 small molecule active

    1 trial

  17. ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

    Lxo Ireland Designated Activity Company

    Sars-CoV2

    phase 2 small molecule completed

    1 trial

  18. ALN-2232

    Alnylam Netherlands B.V.

    Obesity

    phase 2 small molecule active

    1 trial

  19. ALN-4324

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule active

    1 trial

  20. ALN-4324

    Alnylam Netherlands B.V.

    Obese or Overweight Healthy Volunteers

    phase 2 small molecule active

    1 trial

  21. ALN-6400

    Alnylam Netherlands B.V.

    Hereditary Hemorrhagic Telangiectasia

    phase 2 small molecule active

    1 trial

  22. ALN-6400

    Alnylam Netherlands B.V.

    Von Willebrand Disease (VWD)

    phase 2 small molecule active

    1 trial

  23. ALN-AAT02

    Alnylam Netherlands B.V.

    ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

    phase 2 small molecule terminated

    1 trial

  24. ALN-AGT01 RVR

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule active

    1 trial

  25. ALN-ANG3

    Regeneron UK Limited

    Diabetic Kidney Disease (DKD)

    phase 2 small molecule active

    1 trial

  26. ALN-CC5

    Alnylam Netherlands B.V.

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule completed

    1 trial

  27. ALN-CFB

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule active

    1 trial

  28. ALN-CIDEB

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 2 small molecule active

    1 trial

  29. ALN-HSD

    Regeneron UK Limited

    Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

    phase 2 small molecule active

    1 trial

  30. ALN-KHK

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule terminated

    1 trial

  31. ALN-PNP

    Regeneron UK Limited

    Healthy Volunteers

    phase 2 small molecule active

    1 trial

  32. ALN-PNP

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    phase 2 small molecule active

    1 trial

  33. ALN-RSV01

    Alnylam Netherlands B.V.

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    3 trials

  34. ALN-SOD

    Regeneron UK Limited

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  35. ALN-TTR02 (patisiran) administered by intravenous (IV) infusion

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  36. ALN-TTRSC (revusiran) for subcutaneous administration

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  37. ALN-XDH

    Alnylam Netherlands B.V.

    Gout

    phase 2 small molecule terminated

    1 trial

  38. ALPN-101

    Vertex Pharmaceuticals (Australia) Pty.

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  39. ALX-0061

    Sanofi Pasteur

    Lupus Erythematosus, Systemic

    phase 2 mab completed

    1 trial

  40. ALX-0600

    Takeda

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  41. ALX1-11 50 mcg

    Takeda

    Osteoporosis

    phase 2 small molecule completed

    1 trial

  42. ALXN 2040, Placebo matching ALXN2040

    Alexion Europe SAS

    Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)

    phase 2 small molecule active

    1 trial

  43. ALXN 2050, ALXN2050 Placebo Tablets

    Alexion Europe SAS

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  44. ALXN1210-NEPH-202

    Alexion Europe SAS

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  45. ALXN2350-DCM-201

    Alexion Europe SAS

    BAG3 Mutation Associated Dilated Cardiomyopathy

    phase 2 small molecule active

    1 trial

  46. ALXN2420-Acro-201

    Alexion Europe SAS

    Acromegaly

    phase 2 small molecule active

    1 trial

  47. AMBROXOL , Microcrystalline cellulose

    Disc Medicine

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  48. AMG 133, Placebo for AMG 133

    Amgen

    Overweight and Obesity

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.